US64051A1016
© Globe Newswire
15.12.2025
NTHI
LISTED
NASDAQ
NeOnc Technologies Reports Updated Clinical Results
News Preview
Expanded Clinical Experience Demonstrates Additional Long-Term Survival and Radiographic Remission in Recurrent Grade III/IV IDH1-Mutant Astrocytoma Treated with Intranasal NEO100 Expanded Clinical Experience Demonstrates Additional Long-Term Survival and Radiographic Remission in Recurrent Grade III/IV IDH1-Mutant Astrocytoma Treated with Intranas...
Themefolio
Profiler
Peergroup
© Globe Newswire
01.12.2025
NTHI
LISTED
NASDAQ
NeOnc Technologies (Nasdaq: NTHI) Announces AI-Driven Findings Showing Ultrasound Enhances the Potency of an Already Effective NEO100 in Treating Primary and Metastatic Brain Tumors
News Preview
CALABASAS, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI), a clinical-stage biopharmaceutical company developing brain-penetrant therapeutics for central nervous system (CNS) cancers, today announced newly published preclinical findings from a research collaboration at the University of Southern Califor...
Themefolio
Profiler
Peergroup
© Globe Newswire
14.11.2025
NTHI
LISTED
NASDAQ
NeOnc Technologies Holdings Reports Third Quarter 2025 Results and Provides Operational Update
News Preview
CALABASAS, Calif., Nov. 14, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NTHI) (“NeOnc” or the “Company”), a multi-Phase 2 clinical-stage biopharmaceutical company pioneering therapies for central nervous system (CNS) cancers, today announced financial results for the quarter ended September 30, 2025, and provided an update on rece...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Short sale statistics, hedge fund activities and much more user-friendly information
© Globe Newswire
07.11.2025
NTHI
LISTED
NASDAQ
NeOnc Technologies (Nasdaq: NTHI) to Host Investor Conference Call to Present Data Updates from Ongoing NEO100-1 Phase 1/2a Clinical Trial and Compassionate Use Program
News Preview
CALABASAS, Calif., Nov. 07, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NTHI) (“NeOnc” or the “Company”), a clinical-stage biopharmaceutical company developing novel brain-penetrant therapeutics for patients with malignant brain tumors and central nervous system (CNS) disorders, today announced that it will host an investor confer...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© Globe Newswire
28.10.2025
NTHI
LISTED
NASDAQ
His Highness Sheikh Nahyan bin Zayed Al Nahyan Assumes Executive Chairmanship of NeOnc Technologies' Subsidiary, NuroMENA, Pioneering UAE-US Partnership in Brain Cancer Treatment
News Preview
CALABASAS, Calif. and ABU DHABI, United Arab Emirates, Oct. 28, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NTHI) (“NeOnc” or the “Company”), a multi-Phase 2 clinical-stage biopharmaceutical company pioneering therapies for central nervous system (CNS) cancers, announces a landmark development for global healthcare innovation, His...
Themefolio
Profiler
Peergroup
© Globe Newswire
09.10.2025
NTHI
LISTED
NASDAQ
NeOnc Technologies' Subsidiary, NuroMENA, Signs Master Services Agreement with M42’s IROS and Expands Board of Directors
News Preview
CALABASAS, Calif. and ABU DHABI, United Arab Emirates, Oct. 09, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NTHI) (“NeOnc” or the “Company”), a multi-Phase 2 clinical-stage biopharmaceutical company pioneering therapies for central nervous system (CNS) cancers, has announced two major strategic developments that solidify its expan...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
06.10.2025
NTHI
LISTED
NASDAQ
New to The Street to Broadcast Tonight on Fox Business 10:30 PM PST Featuring NeOnc Technologies, FLOKI, XION, Sharps Technology, and Aeries Technology
News Preview
NEW YORK CITY, NEW YORK / ACCESS Newswire / October 6, 2025 / New to The Street, one of America's longest-running business television brands, announces tonight's nationwide broadcast on Fox Business at 10:30 PM PST. The episode features exclusive interviews with NeOnc Technologies (NASDAQ:NTHI), FLOKI, XION, Sharps Technology (NASDAQ:STSS), and Aer...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.10.2025
NTHI
LISTED
NASDAQ
NeOnc Technologies and Quazar Investment Set to Close $50 Million Strategic Partnership by October 23rd Following Final UAE Tax Approvals
News Preview
CALABASAS, Calif., Oct. 06, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NTHI) (“NeOnc” or the “Company”), a multi-Phase 2 clinical-stage biopharmaceutical company pioneering therapies for central nervous system (CNS) cancers, today announced a significant milestone in its partnership with Quazar Investment. Following the receipt o...
Themefolio
Profiler
Peergroup
© Globe Newswire
02.10.2025
NTHI
LISTED
NASDAQ
NeOnc Technologies Appoints Dr. David M. Ashley, Director of The Preston Robert Tisch Brain Tumor Center at Duke, to Scientific Advisory Board
News Preview
CALABASAS, Calif., Oct. 02, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NTHI) (“NeOnc” or the “Company”), a multi-Phase 2 clinical-stage biopharmaceutical company pioneering therapies for central nervous system (CNS) cancers, today announced it has appointed Dr. David M. Ashley to its scientific advisory board. Dr. Ashley is the R...
Themefolio
Profiler
Peergroup
© Globe Newswire
29.09.2025
NTHI
LISTED
NASDAQ
NeOnc Technologies Appoints Renowned Neuro-Oncologist Dr. Henry S. Friedman to Scientific Advisory Board
News Preview
CALABASAS, Calif., Sept. 29, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NTHI) (“NeOnc” or the “Company”), a multi-Phase 2 clinical-stage biopharmaceutical company pioneering therapies for central nervous system (CNS) cancers, today announced it has appointed Dr. Henry S. Friedman to its scientific advisory board. Dr. Friedman is...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
26.09.2025
NTHI
LISTED
NASDAQ
New to The Street to Broadcast Saturday, September 27th Featuring NeOnc Pharma $NTHI and Other Innovative Companies
News Preview
Bloomberg Television 6:30 PM ET as Sponsored Programming - With TV Commercials Debuting by Laser Photonics $LASE, Synergy CHC $SNYR, Sustainable Green Team $SGTM, and Acurx Pharmaceuticals $ACXP NEW YORK CITY, NEW YORK / ACCESS Newswire / September 26, 2025 / New to The Street, a leading national business television series, announces its upcoming b...
Themefolio
Profiler
Peergroup
© Globe Newswire
22.09.2025
NTHI
LISTED
NASDAQ
NeOnc Technologies to Showcase Progress on Addressing Brain Cancer to 63 Million TV Households on “Health Uncensored with Dr. Drew” on the Lifetime Network on September 25, premiering nationwide at 8:00 a.m. ET/PT
News Preview
CALABASAS, Calif., Sept. 22, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ:NTHI), a multi-Phase 2 clinical-stage biotechnology company pioneering therapies for central nervous system (CNS) cancers, will be featured on Health Uncensored hosted by Dr. Drew Pinsky. The episode is scheduled to air on the Lifetime Network, availab...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© ACCESSWIRE
13.09.2025
NTHI
LISTED
NASDAQ
New to The Street to Broadcast Episode 686 Tonight on Bloomberg Television at 6:30 PM EST
News Preview
NEW YORK CITY, NY / ACCESS Newswire / September 13, 2025 / New to The Street, one of America's longest-running financial media television platforms, will air its 686th episode nationwide on Bloomberg Television tonight, Saturday, September 13, 2025, at 6:30 PM EST.This milestone episode will spotlight four innovative companies making waves in their...
Themefolio
Profiler
Peergroup
© Globe Newswire
10.09.2025
NTHI
LISTED
NASDAQ
NeOnc Technologies Receives FDA Authorization to Proceed with Phase II Clinical Trial of NEO212 – A First-in-Class Oral Chemical Conjugated Chemotherapy Candidate for Brain Cancer
News Preview
CALABASAS, Calif., Sept. 10, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI) (“NeOnc” or the “Company”), a multi-Phase 2 clinical-stage biopharmaceutical company pioneering therapies for central nervous system (CNS) cancers, today announced that the U.S. Food and Drug Administration (FDA) has authorized the Company to pr...
Themefolio
Profiler
Peergroup
© Globe Newswire
25.08.2025
NTHI
LISTED
NASDAQ
NeOnc Technologies Closes Strategic Acquisition of Advanced AI and 3D Bioprinting IP, Appointing World-Renowned Scientist Dr. Ishwar K. Puri to its Board
News Preview
CALABASAS, Calif., Aug. 25, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ:NTHI), a multi-Phase 2 clinical-stage biotechnology company pioneering therapies for central nervous system (CNS) cancers, today announced the closing of its acquisition of an intellectual property portfolio featuring artificial intelligence, 3D bioprin...
Themefolio
Profiler
Peergroup
© Globe Newswire
19.08.2025
NTHI
LISTED
NASDAQ
NeOnc Technologies Holdings Reports Second Quarter 2025 Results and Provides Operational Update
News Preview
CALABASAS, Calif. and ABU DHABI, United Arab Emirates, Aug. 19, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI), a multi–Phase 2 clinical-stage biotechnology company pioneering therapies for central nervous system (CNS) cancers, today announced financial results for the quarter ended June 30, 2025, and provided an update...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
11.08.2025
NTHI
LISTED
NASDAQ
New to The Street's Esteemed Client NeOnc Technologies Finalizes $50 Million Strategic Partnership with Quazar Investment as NuroMENA Holdings Receives ADGM Incorporation
News Preview
CALABASAS, CA AND ABU DHABI, UAE / ACCESS Newswire / August 11, 2025 / NeOnc Technologies Holdings, Inc. (NASDAQ:NTHI), a multi-Phase 2 clinical-stage biotechnology company pioneering therapies for central nervous system (CNS) cancers, today announced the official incorporation of NuroMENA Holdings Ltd. by the Abu Dhabi Global Market (ADGM). This m...
Themefolio
Profiler
Peergroup
© Globe Newswire
11.08.2025
NTHI
LISTED
NASDAQ
NeOnc Technologies Finalizes All Contingencies for $50 Million Strategic Partnership with Quazar Investment as NuroMENA Holdings Receives ADGM Incorporation
News Preview
...
Themefolio
Profiler
Peergroup
© Globe Newswire
07.08.2025
NTHI
LISTED
NASDAQ
NeOnc Technologies Awarded $2.5 Million in NIH STTR Grants to Advance NEO212 in Gliomas and Leukemia
News Preview
CALABASAS, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI), a multi–Phase 2 clinical-stage biotechnology company focused on breakthrough therapies for central nervous system (CNS) malignancies, today announced the award of two competitive NIH STTR (Small Business Technology Transfer) grants totaling $2.5...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
30.07.2025
NTHI
LISTED
NASDAQ
New to The Street Signs NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI) to 12-Part National Broadcast Series Including T.V. Network Features, Earned Media, Commercials, and Iconic Outdoor Billboards
News Preview
NEW YORK CITY, NEW YORK / ACCESS Newswire / July 30, 2025 / New to The Street, the nation's premier financial media platform for emerging public companies, proudly announces a major media partnership with NeOnc Technologies Holdings, Inc. (NASDAQ:NTHI). Under this agreement, NeOnc will be featured in a 12-part national broadcast series, with exclus...
Themefolio
Profiler
Peergroup
© Globe Newswire
30.07.2025
NTHI
LISTED
NASDAQ
NeOnc Technologies Signs Definitive Agreement to Acquire AI, 3D, and Quantum Modeling IP Portfolio from Dr. Ishwar K. Puri; Appoints Him to Board of Directors
News Preview
CALABASAS, Calif., July 30, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI), a multi Phase 2 clinical-stage biotechnology company pioneering innovative treatments for brain cancers, is proud to announce the signing of a definitive, binding Letter of Intent (LOI) to acquire all outstanding equity interests in a to-be-form...
Themefolio
Profiler
Peergroup
© Globe Newswire
28.07.2025
NTHI
LISTED
NASDAQ
NeOnc Technologies to Participate at the BTIG Virtual Biotechnology Conference
News Preview
CALABASAS, Calif., July 28, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI), a clinical-stage biotechnology company advancing transformative treatments for brain and central nervous system cancers, today announced that management will participate in the BTIG Virtual Biotechnology Conference, being held on July 29-30, 202...
Themefolio
Profiler
Peergroup
© Globe Newswire
23.07.2025
NTHI
LISTED
NASDAQ
CORRECTING and REPLACING - NeOnc Technologies Holdings, Inc.
News Preview
CALABASAS, Calif., July 23, 2025 (GLOBE NEWSWIRE) -- In a press release issued earlier today by NeOnc Technologies Holdings, Inc. under the headline, "NeOnc Technologies’ Executive Chairman to Be Featured in Live Interview with Kenny Polcari on YouTube.com/@Floorstocks — Today at 11:00 a.m. ET," please note "today" in the headline and first parag...
Themefolio
Profiler
Peergroup
© Globe Newswire
23.07.2025
NTHI
LISTED
NASDAQ
NeOnc Technologies’ Executive Chairman to Be Featured in Live Interview with Kenny Polcari on YouTube.com/@Floorstocks — Today at 11:00 a.m. ET
News Preview
CALABASAS, Calif., July 23, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NTHI), a clinical-stage biotechnology company advancing transformative treatments for brain and central nervous system cancers, is pleased to announce that its Executive Chairman & President, Amir Heshmatpour, will be featured in a live interview with prom...
Themefolio
Profiler
Peergroup
© Globe Newswire
08.07.2025
NTHI
LISTED
NASDAQ
NeOnc Technologies Signs $50 Million Non-Binding Strategic Term Sheet with Quazar Investment to Launch GCC & MENA Expansion and Clinical Trials Platform
News Preview
CALABASAS, Calif., July 08, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI), a clinical-stage biotechnology company advancing transformative treatments for brain and central nervous system cancers, today announced it has signed a non-binding term sheet with Quazar Investment to form a new UAE-based investment and clinica...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.06.2025
NTHI
LISTED
NASDAQ
NeOnc Technologies Holdings, Inc. Appoints Dr. Josh Neman as Chief Clinical Officer to Advance Clinical Strategy and Translational Oncology Programs
News Preview
USC brain tumor authority to accelerate four clinical trials including lead asset NEO100 nearing Phase 2a completion ahead of schedule...
Themefolio
Profiler
Peergroup
© Globe Newswire
15.04.2025
NTHI
LISTED
NASDAQ
NeOnc Technologies Global Patent Portfolio Covers Core Pipeline Across All Major Pharmaceutical Markets
News Preview
-- 176 Patents Issued and Outstanding Reinforces NeOnc’s Competitive Position -- CALABASAS, Calif., April 15, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI), a biopharmaceutical company focused on the development of novel oncology and neurology therapeutics, today announced that its global patent portfolio totals 176, r...
Themefolio
Profiler
Peergroup
© Globe Newswire
10.04.2025
NTHI
LISTED
NASDAQ
الرئيس التنفيذي لشركة NeOnc Technologies Holdings, Inc.، Amir Heshmatpour، يتولى دورًا قياديًا مُوسّعًا بصفته الرئيس الجديد للشركة
News Preview
كالاباساس، كاليفورنيا،, April 10, 2025 (GLOBE NEWSWIRE) -- أعلنت اليوم شركة NeOnc Technologies Holdings, Inc. (المدرجة في بورصة NASDAQ تحت الرمز NTHI)، وهي شركة لتصنيع الأدوية الحيوية في المرحلة السريرية تركز على العلاجات المبتكرة لسرطانات واضطرابات الجهاز العصبي المركزي (CNS)، عن تعيين الرئيس التنفيذي، Amir Heshmatpour، في منصب رئيس الشركة. سيحت...
Themefolio
Profiler
Peergroup
© Globe Newswire
10.04.2025
NTHI
LISTED
NASDAQ
NeOnc Technologies Holdings, Inc. Executive Chairman, Amir Heshmatpour, Assumes Expanded Leadership Role as Company’s New President
News Preview
CALABASAS, Calif., April 10, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI), a clinical-stage biopharmaceutical company focused on innovative treatments for central nervous system (CNS) cancers and disorders, today announced that Executive Chairman Amir Heshmatpour has been appointed to serve as President of the Company...
Themefolio
Profiler
Peergroup
© Globe Newswire
31.03.2025
NTHI
LISTED
NASDAQ
NeOnc Technologies Holdings, Inc. Receives Rare Pediatric Disease Designation for NEO100 in Treatment of Pediatric-Type Diffuse High-Grade Gliomas
News Preview
WESTLAKE VILLAGE, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ Global Market: NTHI), a clinical-stage medical biotechnology company, today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation (RPDD) to perillyl alcohol (NEO100™) for the treatment of pedia...
Themefolio
Profiler
Peergroup
© Globe Newswire
27.03.2025
NTHI
LISTED
NASDAQ
NeOnc Technologies Expands Global Clinical Trial Network with CBCC Global Research to Accelerate Study of Brain Cancer Treatments
News Preview
WESTLAKE VILLAGE, Calif., March 27, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (Nasdaq Global Market: NTHI), a clinical-stage medical biotechnology company, today announced a strategic partnership with CBCC Global Research (CBCC), a premier full-service clinical research organization (CRO). This collaboration will expand NeOnc’s c...
Themefolio
Profiler
Peergroup
© Globe Newswire
25.03.2025
NTHI
LISTED
NASDAQ
NEONC Technologies Holdings, Inc. Appoints Dr. Alan Chiang to its Board of Directors
News Preview
Dr. Chaing Expands NeOnc’s Expertise in Neurosurgery and Biotechnology Dr. Chaing Expands NeOnc’s Expertise in Neurosurgery and Biotechnology...
Themefolio
Profiler
Peergroup
© Globe Newswire
25.03.2025
NTHI
LISTED
NASDAQ
NEONC Technologies Holdings, Inc. Appoints Renowned Neurosurgeon Dr. Steven L. Giannotta to its Board of Directors
News Preview
Dr. Giannotta brings extensive cerebrovascular and cranial base surgery experience and expertise to the NeOnc team Dr. Giannotta brings extensive cerebrovascular and cranial base surgery experience and expertise to the NeOnc team...
Themefolio
Profiler
Peergroup
© Globe Newswire
26.06.2024
NTHI
LISTED
NASDAQ
NeOnc Technologies Completes $18.5 Million Financing, Advances Phase II Clinical Trials for Enhanced Method of Delivering Novel Therapeutics to the Brain Under FDA Fast-Track Status
News Preview
WESTLAKE VILLAGE, Calif., June 26, 2024 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc., a clinical-stage medical biotechnology company, has completed a $18.5 million financing to support the ongoing development and Phase I and II clinical studies of its novel drug and delivery methods designed to address the persistent challenges with ove...
Themefolio
Profiler
Peergroup
© Globe Newswire
15.05.2024
NTHI
LISTED
NASDAQ
NeOnc Technologies Wins California Investment Forum’s Breakthrough Medical Technology Achievement Award
News Preview
Clinical-Stage Biopharmaceutical Company Receives Recognition of Novel Therapeutics and Drug Delivery Methods for Treating Brain and Central Nervous System Diseases Clinical-Stage Biopharmaceutical Company Receives Recognition of Novel Therapeutics and Drug Delivery Methods for Treating Brain and Central Nervous System Diseases...
Themefolio
Profiler
Peergroup
© Globe Newswire
09.05.2024
NTHI
LISTED
NASDAQ
NeOnc Technologies Invited to Present at California Investment Forum in Anaheim on May 10
News Preview
SoCal-based Clinical-Stage Biopharmaceutical Company Focused on Novel Therapeutics for Brain and Central Nervous System Diseases Nominated for Breakthrough Medical Technology Achievement Award SoCal-based Clinical-Stage Biopharmaceutical Company Focused on Novel Therapeutics for Brain and Central Nervous System Diseases Nominated for Breakthrough M...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
